We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
HER-2/neu is an independent prognostic factor in type I endometrial adenocarcinoma.
- Authors
Kalogiannidis, Ioannis; Petousis, Stamatios; Bobos, Mattheos; Margioula-Siarkou, Chrysoula; Topalidou, Maria; Papanikolaou, Alexis; Vergote, Ignace; Agorastos, Theodoros
- Abstract
Purpose: Το define the prognostic significance of HER-2/neu and PTEN expression in patients with endometrioid (type I) endometrial cancer. Methods: Seventy-seven patients with endometrioid endometrial carcinoma were included in the study, in a period between 1996 and 2009. Patients with coexisting malignancy and those having incomplete immunohistochemical data or clinical follow-up were excluded. Histological staging was defined according to the revised FIGO staging (2009). Clinico-pathologic and immunohistochemical characteristics were correlated in a multivariate Cox regression analysis with overall survival (OS), cancer-related survival (CRS) and disease-free survival (DFS). Results: Mean age of the patients was 62.7 years. The median follow-up was 67 months (9-124 months). HER-2/neu expression was detected in 18.2 % ( n = 14), and PTEN expression in 72.7 % ( n = 56) of our patients. Multivariate Cox regression analysis showed that patient's age, FIGO staging and HER-2/neu expression were independent prognostic factors for OS, CRS and DFS. PTEN expression did not significantly affect survival outcomes of the present study. Conclusions: HER-2/neu but not PTEN expression is an independent prognostic factor for type I endometrial carcinoma.
- Subjects
PROTEIN expression; HER2 protein; CANCER in women; ENDOMETRIAL cancer; PROTO-oncogenes; TUMOR proteins; HEALTH outcome assessment; PROGNOSIS
- Publication
Archives of Gynecology & Obstetrics, 2014, Vol 290, Issue 6, p1231
- ISSN
0932-0067
- Publication type
Article
- DOI
10.1007/s00404-014-3333-2